continuous infusion

Type: Keyphrase
Name: continuous infusion
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Pfizer : Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA BeneFIX® Once-Weekly Prophylaxis For Hemophilia B

By a News Reporter-Staff News Editor at Pharma Business Week -- Pfizer Inc. (NYSE:PFE) announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand ... [Published 4 Traders - Jul 24 2014]
First reported Jul 19 2014 - Updated Jul 19 2014 - 1 reports

Continuous infusions of meropenem in ambulatory care reviewed

“We retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1% (2.4 g) or 2% (4.8 ... [Published IVTEAM - Jul 19 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

The Case Against Benzodiazepine Use in the ICU

Sedatives in the ICU: Is There a Better Choice?I first blogged about sedative agents in the intensive care unit (ICU) soon after the 2013 clinical practice guideline (CPG) on ICU management of pain, agitation, and delirium was published. [1] In contrast ... [Published General Medicine eJournal - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 2 reports

UPDATE: Pfizer Shares Higher After Finding Statistically Significant Reduction Related to NONACOG ALFA

Pfizer Inc. (NYSE: PFE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia ... [Published Benzinga.com - Jul 16 2014]
First reported Jul 13 2014 - Updated Jul 13 2014 - 1 reports

FLAMEL TECHNOLOGIES : Gets OK from FDA for Vazculep

Flamel Technologies said that the U.S. Food and Drug Administration has approved the company's New Drug Application for Vazculep.According to a release from the company, Vazculep Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment ... [Published 4 Traders - Jul 13 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 1 reports

Palace awaits recommendation on NFA revamp

MANILA, Philippines - Malacañang is awaiting the recommendation of presidential assistant for food security and agricultural modernization Francis Pangilinan and the National Food Authority on whether to revamp the NFA amid reports of collusion among ... [Published Philippine Star - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Awarded Second Grant from The Michael J. Fox Foundation for Parkinson's Research

Apomorphine, a potent dopamine agonist, is the only drug approved specifically for the treatment of acute motor fluctuations/hypomobility (freezing or "off" episodes) in patients with advanced Parkinson`s disease. Presently, apomorphine is administered ... [Published Indianapolis Business Journal - Jul 08 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Review of an OPAT service with continuous infusions in Japan

“Our experience shows OPAT with continuous infusion is safe and feasible practice not only for improving the QOL of patients but also for efficient bed utilization and medical cost savings.” Hase et al (2014).Reference:Hase, R., Hosokawa, N., Uno, S., ... [Published IVTEAM - Jul 01 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Flamel Technologies Announces FDA Approval of VAZCULEP

LYON, FRANCE--(Marketwired - Jun 30, 2014) - Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for VAZCULEPT (phenylephrine hydrochloride). VAZCULEP ... [Published Marketwire - Breaking News Releases - Jun 30 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

Brave Bowers abseils down Spinnaker Tower in aid of JDRF

Hats off to Samantha Bowers, a member of TM Solutions' Business Partner Support team, who abseiled down Portsmouth's Spinnaker Tower in aid of JDRF, the charitable funder of Type 1 diabetes research.Bowers, whose youngest daughter has Type 1 diabetes, ... [Published Comms Dealer - Jun 30 2014]
First reported Jun 28 2014 - Updated Jun 28 2014 - 1 reports

Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial

ResearchAlberto Palazzuoli , Marco Pellegrini , Gaetano M Ruocco , Giuseppe Martini , Beatrice Franci , Maria Stella Campagna , Marilyn Gilleman , Ranuccio Nuti , Peter A McCullough and Claudio RoncoCritical Care 2014, 18 :R134doi:10.1186/cc13952Published: ... [Published Critical Care - Jun 28 2014]
First reported Jun 21 2014 - Updated Jun 21 2014 - 1 reports

Using Pharmacokinetics to Optimize Older Chemotherapeutic Agents

The landscape of cancer therapy is shifting from traditional cytotoxic chemotherapy towards targeted therapy with agents like tyrosine kinase inhibitors and monoclonal antibodies. However, these newer agents remain costly, and traditional chemotherapy ... [Published Cancernetwork.com - Jun 21 2014]

Quotes

...anagement," said Steven J Romano , M D , senior vice president and Medicines Development Group Head, Global Innovative Pharmaceuticals , Pfizer Inc. " Pfizer remains committed to the researchresearch and development of new and innovative products for the hemophilia community."
"We are extremely pleased to receive NDA approval for Vazculep from the FDA ," said Mike Anderson , Chief Executive Officer of Flamel . "This is the second product from the portfolio of UMDs products following the FDA approval of Bloxiverz in May 2013 . Both of these drugs are used by anesthesiologists in hospital settings."
"Typically the composition in the above patent specification comprises from 0.1 to 5%, by weight, preferably 1% to 2% by weight, of Propofol. The water-immiscible solvent, preferably soybean oil, is suitably present in an amount that is from 0.1 to 3% and more suitably from 1 to 3% by weight of the composition. However, the reduction in the oil content makes the injection more painful because of free Propofol in the aqueous phase."

More Content

All (29) | News (27) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Pfizer : Announces Positive Top-Line Results Fr... [Published 4 Traders - Jul 24 2014]
Continuous infusions of meropenem in ambulatory... [Published IVTEAM - Jul 19 2014]
The Case Against Benzodiazepine Use in the ICU [Published General Medicine eJournal - Jul 18 2014]
MicroRNA-140-5p as a tumor suppressor and sensi... [Published PharmCast - Jul 18 2014]
Deep Venous Thrombosis: The “Economy Class Synd... [Published U.S.Pharmacist - Jul 17 2014]
UPDATE: Pfizer Shares Higher After Finding Stat... [Published Benzinga.com - Jul 16 2014]
Pfizer Announces Positive Top-Line Results From... [Published CNBC - Jul 16 2014]
FLAMEL TECHNOLOGIES : Gets OK from FDA for Vazc... [Published 4 Traders - Jul 13 2014]
Stimulating Catheter and Efficacy of the Nerve ... [Published General Medicine eJournal - Jul 11 2014]
Q&A: In Parkinson’s disease, a new treatment fo... [Published Drug Discovery News - Jul 08 2014]
Palace awaits recommendation on NFA revamp [Published Philippine Star - Jul 08 2014]
Cynapsus Therapeutics Inc. : Cynapsus Therapeut... [Published Indianapolis Business Journal - Jul 08 2014]
Patent Issued for Intravenous Propofol Emulsion... [Published HispanicBusiness.com - Jul 02 2014]
Review of an OPAT service with continuous infus... [Published IVTEAM - Jul 01 2014]
Brave Bowers abseils down Spinnaker Tower in ai... [Published Comms Dealer - Jun 30 2014]
Flamel Technologies Announces FDA Approval of V... [Published TVNewsCheck - Jun 30 2014]
Flamel Technologies Announces FDA Approval of V... [Published Marketwire - Breaking News Releases - Jun 30 2014]
Continuous versus bolus intermittent loop diure... [Published Critical Care - Jun 28 2014]
Human medicines European public assessment repo... [Published European Medicines Agency - Jun 26 2014]
Diuretic Response in Acute Heart Failure [Published Theheart.org - Jun 26 2014]
Patent Application Titled "Folding Inserter for... [Published 4 Traders - Jun 26 2014]
Using Pharmacokinetics to Optimize Older Chemot... [Published Cancernetwork.com - Jun 21 2014]
Portola Pharmaceuticals Begins Enrollment in Ph... [Published GlobeNewswire - May 12 2014]
EHR Story for Mother's Day 2014: Even The Forme... [Published Health Care Renewal - May 09 2014]
Methods and compositions for treatment of human... [Published PharmCast - Apr 28 2014]
Portola Pharmaceuticals starts Phase III trial ... [Published Pharmaceutical Business Review - Mar 20 2014]
Portola reports additional positive results fro... [Published Pharmaceutical Business Review - Dec 10 2013]
Novo Nordisk, Roche Diabetes to make insulin pu... [Published PharmaBiz - Nov 25 2013]
Estrogen receptors and methods of use [Published PharmCast - Oct 24 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Flamel Technologies Announces FDA Approval of V... [Published Marketwire - Breaking News Releases - Jun 30 2014]
LYON, FRANCE--(Marketwired - Jun 30, 2014) - Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for VAZCULEPT (phenylephrine hydrochloride). VAZCULEP ...
EHR Story for Mother's Day 2014: Even The Forme... [Published Health Care Renewal - May 09 2014]
[Note to the humorless:  this post is satirical to make a very serious point, a point too often ignored by those who know better.  If you don't like satire, don't read it.]I've been critiqued for posting in too gloomy a manner for some's taste, even those ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.